Epidemiology, Clinical Features, and Disease Severity in Patients With Coronavirus Disease 2019 (COVID-19) in a Children's Hospital in New York City, New York.
Journal
JAMA pediatrics
ISSN: 2168-6211
Titre abrégé: JAMA Pediatr
Pays: United States
ID NLM: 101589544
Informations de publication
Date de publication:
01 10 2020
01 10 2020
Historique:
pubmed:
4
6
2020
medline:
13
11
2020
entrez:
4
6
2020
Statut:
ppublish
Résumé
Descriptions of the coronavirus disease 2019 (COVID-19) experience in pediatrics will help inform clinical practices and infection prevention and control for pediatric facilities. To describe the epidemiology, clinical, and laboratory features of patients with COVID-19 hospitalized at a children's hospital and to compare these parameters between patients hospitalized with and without severe disease. This retrospective review of electronic medical records from a tertiary care academically affiliated children's hospital in New York City, New York, included hospitalized children and adolescents (≤21 years) who were tested based on suspicion for COVID-19 between March 1 to April 15, 2020, and had positive results for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Detection of SARS-CoV-2 from a nasopharyngeal specimen using a reverse transcription-polymerase chain reaction assay. Severe disease as defined by the requirement for mechanical ventilation. Among 50 patients, 27 (54%) were boys and 25 (50%) were Hispanic. The median days from onset of symptoms to admission was 2 days (interquartile range, 1-5 days). Most patients (40 [80%]) had fever or respiratory symptoms (32 [64%]), but 3 patients (6%) with only gastrointestinal tract presentations were identified. Obesity (11 [22%]) was the most prevalent comorbidity. Respiratory support was required for 16 patients (32%), including 9 patients (18%) who required mechanical ventilation. One patient (2%) died. None of 14 infants and 1 of 8 immunocompromised patients had severe disease. Obesity was significantly associated with mechanical ventilation in children 2 years or older (6 of 9 [67%] vs 5 of 25 [20%]; P = .03). Lymphopenia was commonly observed at admission (36 [72%]) but did not differ significantly between those with and without severe disease. Those with severe disease had significantly higher C-reactive protein (median, 8.978 mg/dL [to convert to milligrams per liter, multiply by 10] vs 0.64 mg/dL) and procalcitonin levels (median, 0.31 ng/mL vs 0.17 ng/mL) at admission (P < .001), as well as elevated peak interleukin 6, ferritin, and D-dimer levels during hospitalization. Hydroxychloroquine was administered to 15 patients (30%) but could not be completed for 3. Prolonged test positivity (maximum of 27 days) was observed in 4 patients (8%). In this case series study of children and adolescents hospitalized with COVID-19, the disease had diverse manifestations. Infants and immunocompromised patients were not at increased risk of severe disease. Obesity was significantly associated with disease severity. Elevated inflammatory markers were seen in those with severe disease.
Identifiants
pubmed: 32492092
pii: 2766920
doi: 10.1001/jamapediatrics.2020.2430
pmc: PMC7270880
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e202430Subventions
Organisme : NIAID NIH HHS
ID : L30 AI133789
Pays : United States
Investigateurs
Jason E Zucker
(JE)
Karen P Acker
(KP)
Marc D Foca
(MD)
Shivang S Shah
(SS)
Jennifer Cheng
(J)
Benjamin S Hooe
(BS)
Rebecca F Carlin
(RF)
Francesca Kingery
(F)
Aaron Charnay
(A)
Steve Paik
(S)
Divya Lakhaney
(D)
Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Références
Clin Infect Dis. 2020 Jul 28;71(15):896-897
pubmed: 32271368
JAMA Pediatr. 2020 Apr 8;:
pubmed: 32267485
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
JAMA. 2020 Apr 28;323(16):1612-1614
pubmed: 32191259
Pediatrics. 2020 Jun;145(6):
pubmed: 32179660
Emerg Infect Dis. 2020 Jun;26(6):1266-1273
pubmed: 32160149
Rev Med Interne. 2012 Nov;33(11):628-34
pubmed: 22658164
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288
N Engl J Med. 2020 Apr 23;382(17):1663-1665
pubmed: 32187458
Gastroenterology. 2020 Jul;159(1):81-95
pubmed: 32251668
Pediatr Pulmonol. 2020 May;55(5):1169-1174
pubmed: 32134205
JAMA Netw Open. 2020 Apr 24;3(4):e208857
pubmed: 32330277
JAMA. 2020 Apr 14;323(14):1335
pubmed: 32181795
Med (N Y). 2020 Dec 18;1(1):114-127.e3
pubmed: 32838355